Pfizer
Search results
As a pioneer in antibody-drug conjugates (ADCs), Seagen has led the way in novel cancer therapeutics for more than 20 years. We’re committed to discovering safe and effective solutions to challenging clinical needs.
Dec 14, 2023 · Seagen is a world-leader in ADC technology, a transformative modality that is emerging as a powerful tool across a broad range of cancers designed to preferentially kill cancer cells and limit off-target toxicities.
As a pioneer in antibody–drug conjugates (ADCs), Seagen has led the way in novel cancer therapeutics for more than 20 years. Our research team is highly motivated to build an innovative pipeline of transformative cancer therapeutics accelerated by best-in-class technology platforms.
With Seagen’s proprietary, world-leading Antibody-Drug Conjugate (ADC) technology, together with the scale and strength of Pfizer's capabilities and expertise, we are poised to change the cancer treatment paradigm.
Dec 14, 2023 · Seagen is a world-leader in ADC technology, a transformative modality that is emerging as a powerful tool across a broad range of cancers designed to preferentially kill cancer cells and...
Seagen Inc. (formerly Seattle Genetics, Inc.) is an American biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer.
Dec 12, 2023 · Pfizer said on Tuesday it expects to close its $43 billion deal to buy cancer drugmaker Seagen later this week and plans to create a new oncology division that includes the acquisition early next...
Dec 14, 2023 · Seagen is a world-leader in ADC technology, a transformative modality that is emerging as a powerful tool across a broad range of cancers designed to preferentially kill cancer cells and...
Mar 13, 2023 · Seagen is a pioneer in ADC technology, with four of the twelve total FDA-approved and marketed ADCs using its technology industry-wide. ADCs are a transformative modality that is emerging as a powerful tool across a broad range of cancers designed to preferentially kill cancer cells and limit off-target toxicities.
Mar 13, 2023 · Pfizer has agreed to acquire oncology-focused biotech Seagen for a total enterprise value of $43bn as the US pharmaceutical company refills its drugs pipeline amid a sharp fall in sales of its ...
